Redeye hosts its third Regenerative Medicine/Cell Therapy event. This next-generation medicinal area consists of cell, gene, and RNA therapies. It is one of the fastest-growing areas, with product sales expected to triple and the number of approved therapies to double by 2028. Interesting companies in different areas within the theme will present.

 

The event will begin with an introduction. This is a unique opportunity for investors interested in this space to learn more, hopefully generating new investment ideas.

 

The participating companies will share their equity story, project status, and triggers ahead.

 

Following the presentations, Redeye’s analysts will hold Q&A sessions where questions are open to the audience.

 

Participating companies: 

 

AcouSort
AcouSort is an innovative medical technology company developing critical components for instrumentation in diagnostics, analytics, and cell therapy processing markets. AcouSort’s components allow for the automated refinement of biological samples such as blood or cell preparations, providing instrumentation manufacturers with a state-of-the-art ability to integrate sample processing steps that traditionally have to be performed manually.

 

Amniotics>>

 

Hansa Biopharma>>

 

Circio
Circio Holding ASA (OSE: CRNA) is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare diseases, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes.

 

Combigene
CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking.
Development assets are sourced from an external research network and developed to achieve preclinical/clinical proof of concept. After that, the ambition is for the projects to be co-developed and commercialized through strategic partnerships.

 

NextCell Pharma
NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem and stromal cells from the umbilical cord. NextCell focuses on the research and development of novel stromal cell therapies and also runs a tissue establishment and primary biobank, classified as a healthcare provider.

 

Phase Holograpic
Phase Holographic Imaging (PHI) develops and markets instrumentation for non-invasive time-lapse imaging. The company’s HoloMonitor product line is used for long-term quantitative analysis of living cell cultures, particularly in preclinical research and regenerative medicine.

 

XNK Therapeutics
XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients.